BACKGROUND: Even though the efficacy of Intermittent Preventive Treatment in infants (IPTi) withSulfadoxine-Pyrimethamine (SP) against clinical disease and the absence of its interaction with routine vaccines of the Expanded Immunization Programme (EPI) have been established, there are still some concerns regarding the addition of IPTi, which may increase the work burden and disrupt the routine EPI services especially in Africa where the target immunization coverage remains to be met. However IPTi may also increase the adherence of the community to EPI services and improve EPI coverage, once the benefice of strategy is perceived. METHODS: To assess the impact of IPTi implementation on the coverage of EPI vaccines, 22 health areas of the district of Kolokani were randomized at a 1:1 ratio to either receive IPTi-SP or to serve as a control. The EPI vaccines coverage was assessed using cross-sectional surveys at baseline in November 2006 and after one year of IPTi pilot-implementation in December 2007. RESULTS: At baseline, the proportion of children of 9-23 months who were completely vaccinated (defined as children who received BGG, 3 doses of DTP/Polio, measles and yellow fever vaccines) was 36.7% (95% CI 25.3% -48.0%). After one year of implementation of IPTi-SP using routine health services, the proportion of children completely vaccinated rose to 53.8% in the non intervention zone and 69.5% in the IPTi intervention zone (P <0.001).The proportion of children in the target age groups who received IPTi with each of the 3 vaccinations DTP2, DTP3 and Measles, were 89.2% (95% CI 85.9%-92.0%), 91.0% (95% CI 87.6% -93.7%) and 77.4% (95% CI 70.7%-83.2%) respectively. The corresponding figures in non intervention zone were 2.3% (95% CI 0.9% -4.7%), 2.6% (95% CI 1.0% -5.6%) and 1.7% (95% CI 0.4% - 4.9%). CONCLUSION: This study shows that high coverage of the IPTi can be obtained when the strategy is implemented using routine health services and implementation results in a significant increase in coverage of EPI vaccines in the district of Kolokani, Mali.
RCT Entities:
BACKGROUND: Even though the efficacy of Intermittent Preventive Treatment in infants (IPTi) with Sulfadoxine-Pyrimethamine (SP) against clinical disease and the absence of its interaction with routine vaccines of the Expanded Immunization Programme (EPI) have been established, there are still some concerns regarding the addition of IPTi, which may increase the work burden and disrupt the routine EPI services especially in Africa where the target immunization coverage remains to be met. However IPTi may also increase the adherence of the community to EPI services and improve EPI coverage, once the benefice of strategy is perceived. METHODS: To assess the impact of IPTi implementation on the coverage of EPI vaccines, 22 health areas of the district of Kolokani were randomized at a 1:1 ratio to either receive IPTi-SP or to serve as a control. The EPI vaccines coverage was assessed using cross-sectional surveys at baseline in November 2006 and after one year of IPTi pilot-implementation in December 2007. RESULTS: At baseline, the proportion of children of 9-23 months who were completely vaccinated (defined as children who received BGG, 3 doses of DTP/Polio, measles and yellow fever vaccines) was 36.7% (95% CI 25.3% -48.0%). After one year of implementation of IPTi-SP using routine health services, the proportion of children completely vaccinated rose to 53.8% in the non intervention zone and 69.5% in the IPTi intervention zone (P <0.001).The proportion of children in the target age groups who received IPTi with each of the 3 vaccinations DTP2, DTP3 and Measles, were 89.2% (95% CI 85.9%-92.0%), 91.0% (95% CI 87.6% -93.7%) and 77.4% (95% CI 70.7%-83.2%) respectively. The corresponding figures in non intervention zone were 2.3% (95% CI 0.9% -4.7%), 2.6% (95% CI 1.0% -5.6%) and 1.7% (95% CI 0.4% - 4.9%). CONCLUSION: This study shows that high coverage of the IPTi can be obtained when the strategy is implemented using routine health services and implementation results in a significant increase in coverage of EPI vaccines in the district of Kolokani, Mali.
Authors: D Schellenberg; C Menendez; E Kahigwa; J Aponte; J Vidal; M Tanner; H Mshinda; P Alonso Journal: Lancet Date: 2001-05-12 Impact factor: 79.321
Authors: Alexandra de Sousa; Leon P Rabarijaona; Jean L Ndiaye; Doudou Sow; Mouhamed Ndyiae; Jacques Hassan; Nilda Lambo; Paul Adovohekpe; Flavia Guidetti; Judith Recht; Alphonse Affo Journal: Trop Med Int Health Date: 2011-11-29 Impact factor: 2.622
Authors: Roly D Gosling; Samwel Gesase; Jacklin F Mosha; Ilona Carneiro; Ramadhan Hashim; Martha Lemnge; Frank W Mosha; Brian Greenwood; Daniel Chandramohan Journal: Lancet Date: 2009-09-16 Impact factor: 79.321
Authors: Drissa Coulibaly; Dapa A Diallo; Mahamadou A Thera; Alassane Dicko; Ando B Guindo; Abdoulaye K Koné; Yacouba Cissoko; Seydou Coulibaly; Abdoulaye Djimdé; Kirsten Lyke; Ogobara K Doumbo; Christopher V Plowe Journal: Am J Trop Med Hyg Date: 2002-12 Impact factor: 2.345
Authors: Angela Oyo-Ita; Charles S Wiysonge; Chioma Oringanje; Chukwuemeka E Nwachukwu; Olabisi Oduwole; Martin M Meremikwu Journal: Cochrane Database Syst Rev Date: 2016-07-10
Authors: Sara Cooper; Bey-Marrié Schmidt; Evanson Z Sambala; Alison Swartz; Christopher J Colvin; Natalie Leon; Charles S Wiysonge Journal: Cochrane Database Syst Rev Date: 2021-10-27